Pfizer Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2012; Provides Earnings Guidance for the Year 2013; Reports Asset Impairment Charges for the Fourth Quarter Ended December 31, 2012
For the full year, the company reported net income attributable to the company of $14,570 million or $1.94 per diluted share on revenue of $58,986 million against net income attributable to the company of $10,009 million or $1.27 per diluted share on revenue of $65,259 million for the same period a year ago. Income from continuing operations was $9,518 million or $1.26 per diluted share against $8,395 million or $1.06 per diluted share for the same period a year ago. Income from continuing operations before provision for taxes on income was $12,080 million against $12,304 million for the same period a year ago. Adjusted income was $16,476 million or $2.19 per diluted share compared to $17,839 million or $2.27 per diluted share for the same period a year ago.
The company provided earnings guidance for the year 2013. The company expects a range for revenues of $56.2 to $58.2 billion and for adjusted diluted EPS of $2.20 to $2.30. Adjusted SI&A expenses to be between $15.6 billion and $16.6 billion. Adjusted R&D expenses to be between $6.5 billion and $7.0 billion. Effective tax rate on adjusted income to be approximately 28.0%. Reported diluted EPS to be between $2.20 to $2.30.
The company reported for the fourth quarter, certain asset impairment charges of $366 million compared to $277 million for the same period last year.